Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14296279 | 0.82 | GAA (0.57) | ALDH1A1MAPTHSD17B10KDM4ETSHR | |
| SCHEMBL14468050 | 0.81 | ALDH1A1 (0.43) | ALDH1A1MAPTHSD17B10KDM4ETSHR | |
| SCHEMBL9692477 | 0.79 | CYP1A2 (0.63) | ALDH1A1MAPTTSHRSMN1; SMN2HPGD | |
| SCHEMBL12877516 | 0.76 | NPSR1 (0.41) | ALDH1A1MAPTHSD17B10KDM4ETSHR | |
| SCHEMBL12862879 | 0.76 | HTT (0.45) | ALDH1A1MAPTSMN1; SMN2GAAUSP2 | |
| SCHEMBL4553391 | 0.75 | HTT (0.47) | ALDH1A1SMN1; SMN2HPGDPOLBHTT | |
| SCHEMBL28456006 | 0.75 | GPBAR1 (0.46) | TSHRHPGD | |
| SCHEMBL5861966 | 0.75 | GPBAR1 (0.46) | TSHRHPGD | |
| SCHEMBL14733227 | 0.74 | EGFR (0.42) | ALDH1A1MAPTHSD17B10KDM4ETSHR | |
| SCHEMBL407480 | 0.74 | CA2 (0.44) | ALDH1A1HSD17B10HPGDPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937096-B2 | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-20 | — | — | US | disclosed |
| US-8853263-B2 | Co-therapy for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-07 | — | — | US | disclosed |
| EP-1773835-B1 | PYRIDO-PYRIDO-PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, THERAPEUTIC USE THEREOF FOR TREATING CANCER | SANOFI SA (FR) | 2014-09-24 | — | — | EP | disclosed |
| US-8716231-B2 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-06 | — | — | US | disclosed |
| US-8691867-B2 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-08 | — | — | US | disclosed |
| US-8497298-B2 | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-30 | — | — | US | disclosed |
| US-8492431-B2 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-07-23 | — | — | US | disclosed |
| US-20120065257-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | SMITH-SWINTOSKY VIRGINIA L (US) | 2012-03-15 | — | — | US | disclosed |
| US-8084490-B2 | Sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-27 | — | — | US | disclosed |
| US-7893259-B2 | Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-02-22 | — | — | US | disclosed |
| US-20070293440-A1 | O-fused heterocycle sulfonylurea compounds with another anticonvulsant or antiepileptic agent such as carbamazepine | JANSSEN PHARMACEUTICA NV (BE) | 2007-12-20 | — | — | US | disclosed |
| US-20070191474-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-16 | — | — | US | disclosed |
| US-20070167469-A1 | Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-07-19 | — | — | US | disclosed |
| US-20070155824-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR DISEASE MODIFICATION / EPILEPTOGENESIS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155821-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR LOWERING LIPIDS AND LOWERING BLOOD GLUCOSE LEVELS | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155827-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155826-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155822-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155825-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155823-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES AS NEUROPROTECTIVE AGENTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155822-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | SULT2A1, OPRL1, NPSR1 | ALDH1A1 181/4885MAPT 3521/4885HSD17B10 842/4885 |
| US-20070155823-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES AS NEUROPROTECTIVE AGENTS | SMN1; SMN2, BDNF, SIRT1 | ALDH1A1 379/4885MAPT 457/4885HSD17B10 2007/4885 |
| US-20070155824-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR DISEASE MODIFICATION / EPILEPTOGENESIS | STS, GABRB2, SULT2A1 | ALDH1A1 267/4885MAPT 2435/4885HSD17B10 263/4885 |
| US-20070167469-A1 | Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof | DPYD, PNPO, TYMP | ALDH1A1 407/4885MAPT 2111/4885HSD17B10 2810/4885 |
| US-20070155827-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | SDHA, SQOR, SDHB | ALDH1A1 254/4885MAPT 1847/4885HSD17B10 319/4885 |
| US-20070191474-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | CNR2, FAAH2, CCKBR | ALDH1A1 1511/4885MAPT 2335/4885HSD17B10 1027/4885 |
| US-20070155825-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION | SULT2A1, SULT1A1, STS | ALDH1A1 26/4885MAPT 3356/4885HSD17B10 250/4885 |
| US-20070293440-A1 | O-fused heterocycle sulfonylurea compounds with another anticonvulsant or antiepileptic agent such as carbamazepine | GABBR1, GABRB2, GABRE | ALDH1A1 1032/4885MAPT 2338/4885HSD17B10 654/4885 |
| US-20120065257-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | CNR2, FAAH2, CCKBR | ALDH1A1 1511/4885MAPT 2335/4885HSD17B10 1027/4885 |
| US-20070155826-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER | GABBR1, GABBR2, SQOR | ALDH1A1 503/4885MAPT 1665/4885HSD17B10 246/4885 |
| US-20070155821-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR LOWERING LIPIDS AND LOWERING BLOOD GLUCOSE LEVELS | GPR119, LIPC, GLP1R | ALDH1A1 558/4885MAPT 4214/4885HSD17B10 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.